Pfizer Inc. (NYSE:PFE) announced today that it has entered into an
agreement with Merck KGaA, Darmstadt, Germany, to jointly develop and
commercialize MSB0010718C, an investigational anti-PD-L1 antibody
currently in development by Merck KGaA as a potential treatment for
multiple types of cancer.
for Pfizer Forms Global Strategic Alliance with Merck KGaA, Germany, to Jointly Develop and Commercialize Anti-PD-L1 to Accelerate Presence in Immuno-Oncology investment picks